NSE:VENUSREM (India)
Â
Shs Dematerialised
₹
1,611.5
+32.4 (+2.09%)
Sep 22
Business Description
Venus Remedies Ltd
SIC : 2834
ISIN : INE411B01019
Share Class Description:
NSE:VENUSREM: Shs DematerialisedTotal Employee Number:
1,298Compare
Compare
Traded in other countries / regions
526953.India IPO Date
2006-12-20Description
Venus Remedies Ltd is an Indian pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical formulations. Its product portfolio spans injectables, tablets, capsules, and other dosage forms, with a focus on anti-infectives, oncology, critical care, and pain management. The company also develops and manufactures active pharmaceutical ingredients and has a notable presence in the research-based injectable segment, including antibiotic and anticancer products. Venus Remedies sells its products in India and exports to a large number of countries across Asia, Africa, Latin America, and Europe, supplying hospitals, healthcare institutions, and pharmaceutical distributors. Revenue is generated primarily through the sale of finished formulations, supplemented by contract manufacturing and API sales. The company operates manufacturing facilities in India and invests in research and development, including novel drug delivery technologies and patented products.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.97 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.07 | |||||
Interest Coverage | 4661 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 9.28 | |||||
Beneish M-Score | -2.76 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.9 | |||||
3-Year EBITDA Growth Rate | 31.5 | |||||
3-Year EPS without NRI Growth Rate | 54.6 | |||||
3-Year FCF Growth Rate | 60 | |||||
3-Year Book Growth Rate | 13 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 50.5 | |||||
9-Day RSI | 45.82 | |||||
14-Day RSI | 46.04 | |||||
3-1 Month Momentum % | 4.62 | |||||
6-1 Month Momentum % | 103.34 | |||||
12-1 Month Momentum % | 316.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.44 | |||||
Quick Ratio | 1.64 | |||||
Cash Ratio | 0.61 | |||||
Days Inventory | 103.03 | |||||
Days Sales Outstanding | 46.8 | |||||
Days Payable | 92.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.63 | |||||
Forward Dividend Yield % | 0.63 | |||||
5-Year Yield-on-Cost % | 0.63 | |||||
Shareholder Yield % | 0.97 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 51.02 | |||||
Operating Margin % | 17.24 | |||||
Net Margin % | 14.32 | |||||
EBITDA Margin % | 21.93 | |||||
FCF Margin % | 14.74 | |||||
OCF Margin % | 19.39 | |||||
ROE % | 19.16 | |||||
ROA % | 14.91 | |||||
ROIC % | 20.77 | |||||
3-Year ROIIC % | 39.43 | |||||
ROC (Joel Greenblatt) % | 49.46 | |||||
ROCE % | 23.99 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 18.39 | |||||
Forward PE Ratio | 39.65 | |||||
PE Ratio without NRI | 18.39 | |||||
Shiller PE Ratio | 49.11 | |||||
Price-to-Owner-Earnings | 13.79 | |||||
PEG Ratio | 1.86 | |||||
PS Ratio | 2.62 | |||||
PB Ratio | 3.23 | |||||
Price-to-Tangible-Book | 3.77 | |||||
Price-to-Free-Cash-Flow | 18.09 | |||||
Price-to-Operating-Cash-Flow | 13.72 | |||||
EV-to-EBIT | 13.45 | |||||
EV-to-EBITDA | 11.46 | |||||
EV-to-Revenue | 2.52 | |||||
EV-to-FCF | 17.75 | |||||
Price-to-GF-Value | 3.08 | |||||
Price-to-Projected-FCF | 1.43 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.44 | |||||
Price-to-Graham-Number | 1.87 | |||||
| Price-to-Net-Current-Asset-Value | 10.48 | |||||
Earnings Yield (Greenblatt) % | 7.44 | |||||
FCF Yield % | 5.55 | |||||
Forward Rate of Return (Yacktman) % | 13.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Venus Remedies Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 8,112.7 | ||
| EPS (TTM) (₹) | 86.908 | ||
| Beta | 0.4798 | ||
| 3-Year Sharpe Ratio | 1.23 | ||
| 3-Year Sortino Ratio | 3.56 | ||
| Volatility % | 79.23 | ||
| 14-Day RSI | 46.04 | ||
| 14-Day ATR (₹) | 83.229957 | ||
| 20-Day SMA (₹) | 1622.435 | ||
| 12-1 Month Momentum % | 316.84 | ||
| 52-Week Range (₹) | 424 - 2044.3 | ||
| Shares Outstanding (Mil) | 13.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Venus Remedies Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Venus Remedies Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 10.000000 Cash Dividend | 2026-08-07 | 1,562.70 (+2.02%) |
Show
Entries
Venus Remedies Ltd Frequently Asked Questions
What is Venus Remedies Ltd(NSE:VENUSREM)'s stock price today?
The current price of NSE:VENUSREM is ₹1611.50. The 52 week high of NSE:VENUSREM is ₹2044.30 and 52 week low is ₹424.00.
When is next earnings date of Venus Remedies Ltd(NSE:VENUSREM)?
The next earnings date of Venus Remedies Ltd(NSE:VENUSREM) is .
Does Venus Remedies Ltd(NSE:VENUSREM) pay dividends? If so, how much?
The Dividend Yield %  of Venus Remedies Ltd(NSE:VENUSREM) is 0.63% (As of Today), Highest Dividend Payout Ratio of Venus Remedies Ltd(NSE:VENUSREM) was 0. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Venus Remedies Ltd(NSE:VENUSREM) is 0.63%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers